NDAORALTABLET
Approved
Jun 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
TENORETIC 50 (atenolol and chlorthalidone) by Lavipharm is adrenergic beta-antagonists [moa]. Approved for hypertension, to lower blood pressure, heart failure. First approved in 1984.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TENORETIC 50 is a fixed-dose combination tablet combining atenolol (a beta-adrenergic blocker) and chlorthalidone (a thiazide diuretic) for oral administration. It is indicated for hypertension and heart failure, working by reducing adrenergic stimulation and promoting diuresis to lower blood pressure. The dual mechanism targets both sympathetic tone and fluid volume to achieve antihypertensive effect.
$0.107MPart D
LOE ApproachingMinimal commercial activity with only $107K in Part D spending and 150 claims in 2023; small team likely focused on maintaining legacy patient base rather than growth.
Mechanism of Action
Adrenergic beta-Antagonists
Pharmacologic Class:
beta-Adrenergic Blocker
Indications (3)
Worked on TENORETIC 50 at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.